43 filings
8-K
BMEA
Biomea Fusion Inc
1 Apr 24
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
4:06pm
8-K
BMEA
Biomea Fusion Inc
1 Apr 24
Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
4:05pm
8-K
BMEA
Biomea Fusion Inc
7 Mar 24
Other Events
4:02pm
8-K
BMEA
Biomea Fusion Inc
10 Jan 24
Other Events
4:06pm
8-K
BMEA
Biomea Fusion Inc
30 Oct 23
Biomea Fusion Reports Third Quarter 2023 Financial Results and Corporate Highlights
4:05pm
8-K
0i2faj
31 Jul 23
Biomea Fusion Reports Second Quarter 2023 Financial Results and Corporate Highlights
4:08pm
8-K
eusfx4z h1
25 Jul 23
BMF-219 Induces Complete Responses in Target Acute Myeloid Leukemia (AML) Patient Population
4:05pm
8-K
opfjgh
15 Jun 23
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
nkkydajdf
2 May 23
Other Events
5:01pm
8-K
ndnvkz4zceld2qaydw
2 May 23
Biomea Fusion Reports First Quarter 2023 Financial Results and Corporate Highlights
4:11pm
8-K
7r3i0190q80fyrxc
3 Apr 23
Biomea Fusion Announces Proposed Public Offering of Common Stock
4:06pm
8-K
4nisv9
28 Mar 23
Regulation FD Disclosure
5:06pm
8-K
3vmrs8o
28 Mar 23
Biomea Fusion Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
4:11pm
8-K
84q91v
12 Jan 23
Biomea Fusion to Present at 41st Annual J.P. Morgan Healthcare Conference and Highlight 2023 Corporate Milestones
4:06pm
8-K
cqjs d24aj
16 Dec 22
Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent Menin Inhibitor BMF-219 in Type 2 Diabetes
4:06pm
8-K
whwttwxw
13 Dec 22
Other Events
4:14pm
8-K
2ww141 ktiqm0ynd5
25 Nov 22
Entry into a Material Definitive Agreement
1:59pm
8-K
vduwf4gp26y zg
7 Nov 22
Biomea Fusion Reports Third Quarter 2022 Financial Results and Business Highlights
4:08pm
8-K
kygts hlm2o1rv
1 Nov 22
Other Events
4:06pm
8-K
874vy
18 Oct 22
Other Events
4:06pm